肺动脉高压药物靶向治疗的展望

肺动脉高压是一种以肺血管重构为特征,以肺血管阻力病理性增高为主要表现的临床综合征。肺动脉高压患者病情常呈进行性发展,最终导致右心衰竭和死亡。肺动脉高压现有的药物治疗在一定程度上改善了患者的症状,提高了生存率,但不能阻止病情的恶化,肺动脉高压患者的长期预后仍不尽人意。近年来,基于对肺动脉高压病理生理机制的深入认识,肺动脉高压的靶向治疗药物也不断涌现,为肺动脉高压的治疗带来了新的希望。现将肺动脉高压靶向治疗药物的研究进展进行综述。

Expectation in targeted drug therapy for pulmonary arterial hypertension

Pulmonary arterial hypertension （PAH） is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, PAH leads to right ventricular failure and premature death. Current therapeutic strategies modestly improve patients’ symptoms, pulmonary hemodynamic and survival. However, none of the current treatments is actually curative and long-term prognosis remains unsatisfactory. Recently, based on the advances in our understanding of PAH pathology, tremendous novel therapeutic targets were provided for treating PAH. This article reviewed recent progress in the therapeutic targeted drugs of pulmonary arterial hypertension.